Groundbreaking Mibairo yeCD7-Targeted CAR-T Therapy yeT-ALL neT-LBL

Muedzo wekiriniki wenguva pfupi yapfuura wakaratidza kufambira mberi kukuru mukurapa kwekudzokazve kana kuti refractory T-cell acute lymphoblastic leukemia (T-ALL) uye T-cell lymphoblastic lymphoma (T-LBL) vachishandisa CD7-targeted chimeric antigen receptor (CAR) T cell therapy. . Ongororo iyi, yakaitwa nechikwata cheHebei Yanda Lu Daopei Hospital uye Lu Daopei Institute of Hematology, yakabata varwere makumi matanhatu vakagamuchira dhigirii rimwe chete remasero eCD7 CAR (NS7CAR) T akasarudzwa.

Migumisiro yekuedza inokurudzira zvikuru. Pakazosvika zuva 28, 94.4% yevarwere vakawana kudzika kwakadzika kuregererwa (CR) mumapfupa emapfupa. Uyezve, pakati pevarwere makumi matatu nevaviri vane chirwere cheextramedullary, 78.1% vakaratidza mhinduro yakanaka, ne56.3% vachiwana kuregererwa kwakakwana uye 21.9% kuwana kuregererwa. Makore maviri ekupona kwese uye kufambira mberi-pasina kusununguka mazinga aive 63.5% uye 53.7%, zvichiteerana.

Uku kurapa kutsva kwakakosha kuchengetedzeka kwayo, ine cytokine release syndrome inoitika mu91.7% yevarwere (kunyanya giredhi 1/2), uye neurotoxicity inoonekwa mu5% yezviitiko. Uyezve, chidzidzo chacho chakawana kuti varwere vakaenderera mberi nekubatanidzwa kwekubatanidza mushure mekuwana CR vaiva nepamusoro-soro-yekusununguka kwekusununguka kwemazinga ekuenzaniswa nevaya vasina.

Kambani yedu iri kuongorora zvakare kugona kweCD7 CAR-T cell therapy nechigadzirwa chedu, ichivavarira kubatsira mukusimudzira marapirwo eT-cell malignancies.

Izvi zvakawanikwa zvinosimbisa kugona kweCD7-yakanangana neCAR-T cell therapy kupa tariro itsva kuvarwere vane refractory kana kudzoka zvakare T-ALL neT-LBL, zvichiratidza chiitiko chakakosha muhondo inoenderera mberi yekurwisa zvirwere izvi zvakaoma.